‘The Odyssey': Tickets For Christopher Nolan's Homer Epic On Sale This Week
Sources at Imax, Universal and other circuits are mum about this, as if Matt Damon's Odysseus character will slay them for making a peep.
More from Deadline
Everything We Know About Christopher Nolan's Next Film – 'The Odyssey': Release Date, Cast And More
'The Odyssey' Is First Film Shot Entirely With Imax Film Cameras: How CEO Rich Gelfond Met Christopher Nolan's Challenge
Tom Holland Says Working On Christopher Nolan's 'The Odyssey' Was "The Job Of A Lifetime"
This is a first that a studio would put a movie's tickets on sale a year in advance. Typically advance ticket sales dates are strategic, i.e., there's generally a two-month lead for a highly anticipated movie like a Star Wars: Force Awakens, and a short lead for movies that are expected to tank, or be semi-controversial, ala Disney's Snow White (11 days before its March 21 release). The thinking behind this is there's a rabid appetite out there for the movie from Nolan's 70MM fans and these showtimes will sell out. Remember, with Nolan's multi-Oscar winner Oppenheimer, people were going to see that movie at midnight and 6 a.m. showtimes in Imax and 70MM given sellouts at normal primetimes.
Nolan's Oppenheimer grossed $191 million at the global box office in Imax, repping 20% of its $975M global haul. Meanwhile, 30 Imax 70MM locations grossed $28.8M worldwide.
Nolan is shooting The Odyssey entirely with Imax film cameras (not digital). He's been a champ of the large format exhibitor since 2008's The Dark Knight for action scenes, as well as 2010's Inception, 2014's Interstellar and 2020's Tenet.
I hear that Odyssey tickets will be on sale for a limited time.
This is Nolan's feature take of the classic Homer Greek epic poem about the Ithaca king's journey home following the Trojan War. Tom Holland plays Odysseus' son Telemachus. The movie also stars Anne Hathaway, Zendaya, Lupita Nyong'o, Robert Pattinson, Charlize Theron and Jon Bernthal.
Best of Deadline
Everything We Know About Amazon's 'Verity' Movie So Far
'Street Fighter' Cast: Who's Who In The Live-Action Arcade Film Adaption
2025-26 Awards Season Calendar: Dates For Emmys, Oscars, Grammys & More
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025Time: 1:00 PM - 1:30 pm, Eastern TimeLocation: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact:Donald DwyerChief Business Officerinfo@ 506-8462 Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@ 506-8462 Media Contact:Mark CorbaeICR 682-8288
Yahoo
12 minutes ago
- Yahoo
Elysium Therapeutics Completes Pre-IND Meeting with FDA for First-Ever Technology Designed to Combat Oral Fentanyl Overdose
Reports alignment with FDA on next steps to progress clinical program for SOOPR™ as a potentially novel rescue therapy for oral fentanyl overdose LYONS, Colo., Aug. 20, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to prevent and reverse overdoses caused by highly potent, synthetic opioids especially when ingested orally, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) focused on a planned first-in-human clinical trial investigating SOOPR™ (Synthetic Opioid Overdose Protection and Reversal) as a rescue treatment for overdoses brought on by synthetic opioids, including fentanyl. "We are grateful for the productive conversation with the FDA and are confident that we have a clear path forward for our SOOPR clinical program," said Greg Sturmer, CEO of Elysium Therapeutics. "We look forward to receiving the formal minutes from our meeting, completing IND-enabling studies, and filing the IND application in the coming year." SOOPR is a rapid-onset, long-acting rescue agent specifically designed to prevent and reverse overdoses from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 12 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization and severe withdrawal symptoms commonly associated with nalmefene and high-dose naloxone products. SOOPR is also designed to provide protection from same-day re-use of opioids. Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus naloxone and a significantly longer duration of action. This profile is especially useful in counteracting oral fentanyl overdoses associated with prolonged fentanyl absorption and exposure that often outlast the short-acting profile of Narcan. Sturmer added: "Improved rescue therapies designed specifically to address fentanyl overdose are urgently needed as currently available short-acting opioid agonists, such as Narcan, do not align with the long-acting profile of synthetic opioid drugs and often induce severe withdrawal symptoms. As a result, 20 to 45% of fentanyl overdose victims initially rescued with naloxone experience a re-narcotization event, which can lead to brain damage and death, and approximately 40% of decedents from an opioid overdose have received Narcan." About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit ContactTiberend Strategic Advisors, Media David Irish Casey McDonald (231) 632-0002 (646) 577-8520 dirish@ cmcdonald@ View original content to download multimedia: SOURCE Elysium Therapeutics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
Brag House Appoints Scott Woller, Accomplished Capital Markets Legal Counsel, to Board of Directors
NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Brag House Holdings, Inc. (NASDAQ: TBH) ('Brag House' or the 'Company'), the Gen Z engagement platform operating at the intersection of gaming, college sports, and digital media, announced today a change to its Board of Directors. The Board approved the appointment of Scott D. Woller as an independent director. In addition, the Company announced that Daniel Fidrya has resigned from his position as a member of the Company's Board of Directors, effective immediately. With these changes, the Company's Board continues to be comprised of five members, three of which are considered independent directors according to Nasdaq Rule 5605(a)(2). Mr. Woller will serve as Chair of the Audit Committee and as a member of the Nominations and Corporate Governance Committee. Mr. Woller currently serves as Senior Counsel at Wachtel Missry LLP, where he advises public and private companies on securities regulation, corporate governance, and corporate transactions. He brings nearly 20 years of experience working with boards, management teams, and investors across multiple industries. 'We are pleased to welcome Scott to our Board,' said Lavell Juan Malloy, Chief Executive Officer. 'His extensive legal expertise and deep background in securities regulation and governance will be invaluable as Brag House continues to execute on its growth strategy. We also want to thank Daniel Fidrya for his contributions to the Board and the Company.' About Brag House Brag House is a leading media technology gaming platform dedicated to transforming casual college gaming into a vibrant, community-driven experience. By seamlessly merging gaming, social interaction, and cutting-edge technology, the Company provides an inclusive and engaging environment for casual gamers while enabling brands to authentically connect with the influential Gen Z demographic. The platform offers live-streaming capabilities, gamification features, and custom tournament services, fostering meaningful engagement between users and brands. For more information, please visit Forward-Looking Statements Certain statements in this announcement are forward-looking statements. Investors can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'is/are likely to,' 'potential,' 'continue' or other similar expressions. These statements are subject to uncertainties and risks including, but not limited to, the risk factors discussed in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. Media ContactFatema BhabrawalaDirector of Media Relationsfbhabrawala@ Investor Relations ContactAdele CareyVP, Investor Relationsir@ in to access your portfolio
